Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects | Zendy

YongSoon Cho | Zendy; Shi Hyang Lee | Zendy; Hyeong-Seok Lim | Zendy; KyunSeop Bae | Zendy

Open Access

Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects

Author(s) -

YongSoon Cho,

Shi Hyang Lee,

Hyeong-Seok Lim,

KyunSeop Bae

Publication year - 2018

Publication title -

journal of korean medical science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.743

H-Index - 66

eISSN - 1598-6357

pISSN - 1011-8934

DOI - 10.3346/jkms.2018.33.e258

Subject(s) - metformin , cmax , medicine , pharmacology , pharmacokinetics , tolerability , extended release , crossover study , adverse effect , diabetes mellitus , endocrinology , placebo , alternative medicine , pathology

FDC tablet exhibited pharmacokinetic equivalence and comparable safety and tolerability to co-administration of corresponding doses of gemigliptin and metformin XR as individual tablets. Trial registry at ClinicalTrials.gov, NCT02056600.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research